Smart Healthcare

Itinai.com biomedical laboratory close up still scene close u 2a5a1238 15e1 44d7 ad99 fe42b30c4e72 1
Itinai.com biomedical laboratory close up still scene close u 2a5a1238 15e1 44d7 ad99 fe42b30c4e72 1

Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study

“`html

Enhanced Treatment for Relapsed T-lymphoblastic Leukemia/Lymphoma

Patients with relapsed or refractory T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) often face limited treatment options. A new study evaluated a combination therapy using daratumumab (Dara) and venetoclax (Ven) with aclarubicin, cytarabine, granulocyte colony-stimulating factor, and etoposide (CAGE) for these patients.

Key Findings:

  • The combined therapy showed a promising remission rate of 57.1% and a complete remission rate of 47.6% in patients.
  • Patients with the early T-cell precursor (ETP) subtype had a significantly higher remission rate compared to non-ETP patients (100% vs. 44.4%).
  • The treatment was well-tolerated by the patients, indicating its safety and tolerability.

This study suggests that the combination of Dara and Ven with the CAGE regimen could offer a valuable treatment option for patients with relapsed or refractory T-ALL/LBL, especially for those with the ETP subtype.

Full Clinical Trial Report
“`

Dr M. Trenton

AI-Powered Health Tools

Interactive AI Tools to Help You Understand Your Health

Solutions for Smart Healthcare

Clinical Research